These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1897286)

  • 21. [Chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis].
    Kawakami K
    Kekkaku; 2002 Aug; 77(8):569-71. PubMed ID: 12235849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Therapeutic trial of a combination of isoniazid, rifampicin and pyrazinamide in the first 2 months of treatment of pulmonary tuberculosis].
    Bellabas M; Khaled S; Khaled NA; Boulahbal F; Chaulet P
    Rev Mal Respir; 1989; 6(1):59-64. PubMed ID: 2648511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. II. Two-month, daily administration study.
    Acocella G; Nonis A; Perna G; Patane E; Gialdroni-Grassi G; Grassi C
    Am Rev Respir Dis; 1988 Oct; 138(4):886-90. PubMed ID: 3202465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated gatifloxacin and reduced rifampicin concentrations in a single-dose interaction study amongst healthy volunteers.
    McIlleron H; Norman J; Kanyok TP; Fourie PB; Horton J; Smith PJ
    J Antimicrob Chemother; 2007 Dec; 60(6):1398-401. PubMed ID: 17951604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Six-month short course chemotherapy containing pyrazinamide for initial treatment of pulmonary tuberculosis].
    Wada M; Yosiyama T; Yosikawa M; Ogata H; Sugie T; Nakasono T; Sugita H
    Kekkaku; 1994 Nov; 69(11):671-80. PubMed ID: 7837720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Side effects of various combinations of rifampin and isoniazid with ethambutol or streptomycin and pyrazinamide in short-term chemotherapy of newly-detected pulmonary tuberculosis].
    Zierski M; Bek E
    Pneumonol Pol; 1980 Jul; 48(7):469-79. PubMed ID: 7433146
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of tuberculosis. Drug combinations, therapeutic problems and results in a 10-year case load].
    Morland L
    Tidsskr Nor Laegeforen; 1990 Nov; 110(28):3608-11. PubMed ID: 2260057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation.
    Milán-Segovia RC; Domínguez-Ramírez AM; Jung-Cook H; Magaña-Aquino M; Romero-Méndez MC; Medellín-Garibay SE; Vigna-Pérez M; Romano-Moreno S
    Int J Tuberc Lung Dis; 2010 Nov; 14(11):1454-60. PubMed ID: 20937187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum concentration of isoniazid following administration of the drug alone and in combination with rifampicin in patients of pulmonary tuberculosis.
    Singhal KC; Rathi R; Kishore K; Varshney SC; Varshney DP
    Indian J Physiol Pharmacol; 1986; 30(1):115-7. PubMed ID: 3818028
    [No Abstract]   [Full Text] [Related]  

  • 31. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report.
    Teo SK
    Int J Tuberc Lung Dis; 1999 Feb; 3(2):126-32. PubMed ID: 10091877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modern treatment of tuberculosis.
    Dutt AK; Stead WW
    Compr Ther; 1982 Sep; 8(9):19-28. PubMed ID: 7140206
    [No Abstract]   [Full Text] [Related]  

  • 33. Tuberculosis treatment: dangerous regimens?
    Rieder HL; Arnadottir T; Trébucq A; Enarson DA
    Int J Tuberc Lung Dis; 2001 Jan; 5(1):1-3. PubMed ID: 11263509
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of pyrazinamide on rifampicin kinetics in patients with tuberculosis.
    Jain A; Mehta VL; Kulshrestha S
    Tuber Lung Dis; 1993 Apr; 74(2):87-90. PubMed ID: 8324212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Studies of short-term chemotherapy of tuberculosis. III. Early and late results of 6 months' treatment of tuberculosis. Analysis of failures and recurrences during 1-5 years' observation].
    Nikodemowicz E; Kamińska M; Kopeć H; Maternowska W; Prus F; Sembratowicz L
    Pneumonol Pol; 1986 Jan; 54(1):9-15. PubMed ID: 3714521
    [No Abstract]   [Full Text] [Related]  

  • 36. Completing tuberculosis prophylaxis in jail: targeting treatment and a comparison of rifampin/pyrazinamide with isoniazid regimens.
    Lambert LA; Ijaz K; Navin TR
    Int J Tuberc Lung Dis; 2005 Feb; 9(2):230; author reply 230-1. PubMed ID: 15732748
    [No Abstract]   [Full Text] [Related]  

  • 37. [New and future drugs in pulmonary tuberculosis].
    Grosset JH; Truffot-Pernot C; Lecoeur H
    Prax Klin Pneumol; 1988 Jun; 42 Suppl 1():206-10. PubMed ID: 3174565
    [No Abstract]   [Full Text] [Related]  

  • 38. [Therapy of tuberculosis in the adult].
    Schrappe M; Wassermann K; Kroegel C
    Med Klin (Munich); 1995 Apr; 90(4):229-30. PubMed ID: 7776936
    [No Abstract]   [Full Text] [Related]  

  • 39. [Results of short-term tuberculosis therapy with isoniazid, rifampicin and pyrazinamide].
    Brändli O; Dreher D; Morger D
    Schweiz Med Wochenschr; 1993 Jun; 123(25):1300-6. PubMed ID: 8341998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Intravenous rifampicin therapy in open tuberculosis].
    Loos U; Musch E; Mackes KG; Reetz KP; Gläser R; Schwabe HK; Hengstmann J; Eichelbaum M
    Med Welt; 1983 Jun; 34(24):701-3. PubMed ID: 6888237
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.